Showing results (61-70 of 102) with videos related to

Sort By:
Pageof 11
The Journal of Rheumatology|April 1, 2005
Effects of prasterone on bone mineral density in women with systemic lupus erythematosus receiving chronic glucocorticoid therapyPhilip J Mease, Ellen M Ginzler, Oscar S Gluck, et al.
British Journal of Clinical Pharmacology|February 25, 2016
A phase I pharmacokinetics trial comparing PF-05280586 (a potential biosimilar) and rituximab in patients with active rheumatoid arthritisStanley Cohen, Paul Emery, Maria Greenwald, et al.
Arthritis and Rheumatism|July 13, 2002
Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusionLarry W Moreland, Rieke Alten, Filip Van den Bosch, et al.
American Journal of Clinical Dermatology|August 7, 2022
Switching Between Adalimumab Reference Product and BI 695501 in Patients with Chronic Plaque Psoriasis (VOLTAIRE-X): A Randomized Controlled TrialAlan Menter, Stanley Cohen, Jonathan Kay, et al.
Seminars in Arthritis and Rheumatism|September 5, 2018
A pooled analysis of the safety of tofacitinib as monotherapy or in combination with background conventional synthetic disease-modifying antirheumatic drugs in a Phase 3 rheumatoid arthritis populationAlan J Kivitz, Stanley Cohen, Edward Keystone, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|September 18, 2021
The Effect of Discontinuing Denosumab in Patients With Rheumatoid Arthritis Treated With GlucocorticoidsKenneth G Saag, Michele T McDermott, Jonathan Adachi, et al.
Annals of the Rheumatic Diseases|June 7, 2017
Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence studyStanley Cohen, Mark C Genovese, Ernest Choy, et al.
Drug Safety|February 2, 2021
Upadacitinib in Rheumatoid Arthritis: A Benefit-Risk Assessment Across a Phase III ProgramPhilip G Conaghan, Eduardo Mysler, Yoshiya Tanaka, et al.
Arthritis Research & Therapy|April 7, 2019
Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension studyJürgen Wollenhaupt, Eun-Bong Lee, Jeffrey R Curtis, et al.
RMD Open|April 19, 2019
Randomised, double-blind, phase III study comparing the infliximab biosimilar, PF-06438179/GP1111, with reference infliximab: efficacy, safety and immunogenicity from week 30 to week 54Rieke Alten, Bogdan Batko, Tomas Hala, et al.
Pageof 11